Clinical Trial Update: Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 proof-of-concept study evaluating the safety and antiviral effect of BZF961 with or without ritonavir boosting in hepatitis C patients completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BZF961 (BZF961)
• Ritonavir (Ritonavir)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hepatitis C | Phase 1, Phase 2 | Status: COMPLETED